Testosterone deficiency and the metabolic syndrome

Aging Male

Volumn 10, Issue 2, 2007, Pages 53-56

  Lunenfeld, Bruno ^a  

^a BAR ILAN UNIVERSITY   (Israel)

Author keywords

Diabetes hypogonadism; Metabolic syndrome; Obesity; Testosterone deprivation

Indexed keywords

CYTOKINE; TESTOSTERONE;

ARTICLE; BODY FAT; BODY MASS; DIET RESTRICTION; GLUCOSE INTOLERANCE; HORMONE DEFICIENCY; HUMAN; HYPOGONADISM; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LEAN BODY WEIGHT; METABOLIC PARAMETERS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; SUPPLEMENTATION; WAIST HIP RATIO;

ANDROGENS; DIABETES MELLITUS, TYPE 2; EVIDENCE-BASED MEDICINE; HUMANS; HYPOGONADISM; ISRAEL; MALE; METABOLIC SYNDROME X; OBESITY; TESTOSTERONE;

EID: 34250209534     PISSN: 13685538     EISSN: 14730790     Source Type: Journal    
DOI: 10.1080/13685530701390800     Document Type: Article

References (58)

1. Bjorntorp P. Abdominal obesity and the metabolic syndrome. Ann Med 1992;24:465-468.
2. Despres JP, Marette A. Relation of components of insulin resistance syndrome to coronary disease risk. Curr Opin Lipidol 1994;5:274-89.
3. Assmann G, Nofer JR, Schulte H. Cardiovascular risk assessment in metabolic syndrome: view from PROCAM. Endocrinol Metab Clin North Am 2004;33:377-392.
4. Ritchie SA, Ewart MA, Perry CG, Connell JM, Salt IP. The role of insulin and the adipocytokines in regulation of vascular endothelial function. Clin Sci (London) 2004;107(6):519-532.
5. Bays H, Mandarino E, Defronzo R. A role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol & Metab 2004;89:463-478.
6. Rigalleau V, Binnert C, Minehira K, Stefanoni N, Schneiter et al. In normal men, free fatty acids reduce peripheral but not splanchnic glucose uptake. Diabetes 2001;50:727-732.
7. Winzell MS, Svensson H, Enerback S, Ravnskjaer K, Mandrup S, et al. Pancreatic beta-cell lipotoxicity induced by overexpression of hormone-sensitive lipase. Diabetes 2003;52(8):2057-2066.
8. McGarry JD, Dobbins RL. Fatty acids, lipotoxicity and insulin secretion. Diabetologia 1999;42:128-138.
9. Festa A, D'Agostino RJ, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42-47.
10. Quinones MJ, Nicholas SB, Lyon CJ. Insulin resistance and the endothelium. Curr Diab Rep 2005;5:246-253.
11. Meade TW, Ruddock V, Stirling Y, et al. Fibrinolytic activity, clotting factors, and long-term incidence of ischemic heart disease in the Northwick Park Heart Study. Lancet 1993;342:1076-1079.
12. Kohler HP, Grant PJ. Mechanisms of disease: plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000;342:1792-1801.
13. Hamsten A, Wiman B, de Faire U, et al. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985;313:1557-1563.
14. Ridker PM, Vaughan DE, Stampfer MJ, et al. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993;341:1165-1168.
15. Tsai AW, Cushman M, Rosamond WD, et al. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002;162:1182-1189.
16. Sobel BE, Woodcock-Mitchell J, Schneider DJ, et al. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation 1998;97:2213-2221.
17. Thompson SG, Kienast J, Pyke SDM, et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995;332:635-641.
18. Hamsten A, de Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987;2:3-9.
19. Ruano M, Silvestre V, Castro R, et al. Morbid obesity, hypertensive disease and the renin-angiotensin-aldosterone axis. Obes Surg 2005;15:670-676.
20. Gerald B. Phillips Relationship between Serum Sex Hormones and Glucose, Insulin, and Lipid Abnormalities in Men with Myocardial Infarction PNAS. 1977;74:1729-1733.
21. Vermeulen A, Goemaere S, Kaufman JM. Sex hormones, body composition and aging. The Aging Male 1999;2:8-16.
22. Van den Beld AW, de Jong FH, Grobbee DE, Pols HA, Lamberts SW. Measures of bio-available testosterone and estradiol and their relationships with muscle strength, bone density and body composition in elderly men. J Clin Endocrinol Metab 2000;85:3276-3282.
23. Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB. Testosterone, sex-hormone-binding globulin and the development of type 2 diabetes mellitus in middle-aged men. Diabetes Care 2000;23:490-494.
24. Laaksonen DE, Niskanen R, Purnonen K, Nuyssönen K, Tuomainen TP, Valkonen VP, Salonen R, Salonen JT. Testosterone and sex-hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004;27:1036-1041.
25. Gyllenborg J, Rasmussen SL, Borch-Johnsen K, Heitmann BL, Skakkebaek NE, Juul A. Cardiovascular risk factors in men: the role of gonadal steroids and sex hormone-binding globulin. Metabolism 2001;50:882-888.
26. Simon D, Charles MA, Nahoul K, Orssaud G, Kremski J, Hully V, Joubert E, Papoz L, Eschwege E. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study. J Clin Endocrinol Metab 1997;82:682-685.
27. Tchernof A, Labrie F, Belanger A, Prud'homme D, Bouchard C, Tremblay A, Nadeau A, Despres JP. Relationships between endogenous steroid hormone, sex hormone-binding globulin and lipoprotein levels in men: contribution of visceral obesity, insulin levels and other metabolic variables. Atherosclerosis 1997;133:235-244.
28. Zmuda JM, Cauley JA, Kriska A, Glynn NW, Gutai JP, Kuller LH. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13 year follow-up of former multiple risk factor intervention trial participants. Am J Epidemiol 1997;146:609-617.
29. Khaw KT, Barrett-Connor E. Blood pressure and endogenous testosterone in men: an inverse relationship. J Hypertens 1988;6:329-332.
30. Haffner SM, Garg A, Peshock RM, Grundy SM. Sex steroid hormones, upper body obesity, and insulin resistance. J Clin Endocrinol Metab 2002;87:4522-4527.
31. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, Mcwhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006;60:762-769.
32. Kaplan SA, Meehan AG, Shah A. The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. What are the implications for the relatively high incidence of erectile dysfunction observed in these men? J Urol 2006;176(4 Pt 1);1524-1527; discussion 1527-1528.
33. Cohen PG. Aromatase, adiposity, aging and disease. The hypogonadal metabolic-atherogenic-disease and aging connection. Med Hypotheses 2001;56:702-708.
34. Holmang A, Bjorntorp P. The effects of testosterone on insulin sensitivity in male rats. Acta Physiol Scand 1992;146:505-510.
35. Muller Grobbee DE, den Tonkelaar I, Lamberts SWJ, van der Schouw YT. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 2005;90:2618-2623.
36. Oh JY, Barrett-Connor E, Wedick NM, Wingard DL. Endogenous sex hormones and the development of type 2 diabetes in older men and women; The Rancho Bernardo study. Diabetes Care 2002;25:55-60.
37. Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006;91(3):843-850.
38. Haffner SM, Valdez RA, Mykkanen L, Stern MP, Katz MS. Decreased testosterone and dehydroepiandrosterone sulfate concentrations are associated with increased insulin and glucose concentrations in nondiabetic men. Metabolism 1994;43:599-603.
39. Haffner SM, Mykkanen L, Valdez RA, Katz MS. Relationship of sex hormones to lipids and lipoproteins in nondiabetic men. J Clin Endocrinol Metab 1993;77(6):1610-1615.
40. Muller M, Grobbee DE, den Tonkelaar I, Lamberts SWJ, van der Schouw YT. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 2005;90:2618-2623.
41. Smith JC, Bennett S, Evans IM, Kynaston HG, Parmar M, Mason MD, Cockcroft JR, Scanlon MF, Davies JS. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. JCEM 2001;86:4261-4267.
42. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24(27):4448-4456.
43. Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, Basaria S. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006;24(24):3979-3983.
44. Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (London) 2003;104(2):195-201.
45. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Berman N, Hull L, Swerdloff RS. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004;89:2085-2098.
46. Bhasin S. Androgen treatment of hypogonadal men. J Clin Endocrinol Metab 1992;74:1221-1224.
47. Bhasin SJ, Buckwalter G. Testosterone supplementation in older men: a rational idea whose time has not yet come. Am J Physiol Endocrinol Metab 2001;281:E1172-E1181.
48. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A, Fabbri A. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol 2005;63:280-293.
49. Wang C, Swerdloff RS, Iranmanesh A, Dobbs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman N. Transdermal testosterone gel improves sexual function, mood, muscle strength and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000;85:2839.
50. Snyder PJ, Peachy H, Hannoush P, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999;84:2647-2653.
51. Woodhouse LJ, Gupta N, Bhasin M, Singh AB, Ross R, Phillips J, Bhasin S. Dose-dependent effects of testosterone on regional adipose tissue distribution in healthy young men. J Clin Endrocrinol Metab 2004;89:718-726.
52. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992;75:1092-1098.
53. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006;154(6):899-906.
54. Marin P, Holmang S, Jonsson L, et al. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord 1992;16:991-997.
55. Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003;6:1-7.
56. Mudali S, Dobs AS. Effects of testosterone on body composition of the ageing male. Mech Ageing Dev 2004;125:297-304.
57. Luukka V, Personen U, Huhtaniemi I. Inverse correlation between serum testosterone and leptin in men. J Clin Endocrinol Metab 1998;81:4433.
58. Hislop MS, Rantanjee BD, Soule SG, Marais AD. Effects of anabolic-androgenic steroid use or gonadal testosterone suppression on serum leptin concentration in men. Eur J Endocrinol 1999;141:40-46.